389 related articles for article (PubMed ID: 29102090)
21. Small Cell Carcinoma of Ovary, Hypercalcemic Type: A Rare Case Report.
Coşkun Ç; Kurucu N; Usubutun A; Soyer T; Ozcan HN; Çelik Ertaş NB; Kutluk T
J Pediatr Adolesc Gynecol; 2023 Apr; 36(2):112-115. PubMed ID: 36243275
[TBL] [Abstract][Full Text] [Related]
22. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2:
Chan-Penebre E; Armstrong K; Drew A; Grassian AR; Feldman I; Knutson SK; Kuplast-Barr K; Roche M; Campbell J; Ho P; Copeland RA; Chesworth R; Smith JJ; Keilhack H; Ribich SA
Mol Cancer Ther; 2017 May; 16(5):850-860. PubMed ID: 28292935
[TBL] [Abstract][Full Text] [Related]
23. Identification of Driver Mutations in Rare Cancers: The Role of SMARCA4 in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT).
Lang JD; Hendricks WPD
Methods Mol Biol; 2018; 1706():367-379. PubMed ID: 29423809
[TBL] [Abstract][Full Text] [Related]
24. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.
Witkowski L; Carrot-Zhang J; Albrecht S; Fahiminiya S; Hamel N; Tomiak E; Grynspan D; Saloustros E; Nadaf J; Rivera B; Gilpin C; Castellsagué E; Silva-Smith R; Plourde F; Wu M; Saskin A; Arseneault M; Karabakhtsian RG; Reilly EA; Ueland FR; Margiolaki A; Pavlakis K; Castellino SM; Lamovec J; Mackay HJ; Roth LM; Ulbright TM; Bender TA; Georgoulias V; Longy M; Berchuck A; Tischkowitz M; Nagel I; Siebert R; Stewart CJ; Arseneau J; McCluggage WG; Clarke BA; Riazalhosseini Y; Hasselblatt M; Majewski J; Foulkes WD
Nat Genet; 2014 May; 46(5):438-43. PubMed ID: 24658002
[TBL] [Abstract][Full Text] [Related]
25. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.
Jelinic P; Mueller JJ; Olvera N; Dao F; Scott SN; Shah R; Gao J; Schultz N; Gonen M; Soslow RA; Berger MF; Levine DA
Nat Genet; 2014 May; 46(5):424-6. PubMed ID: 24658004
[TBL] [Abstract][Full Text] [Related]
26. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
Wang Y; Chen SY; Karnezis AN; Colborne S; Santos ND; Lang JD; Hendricks WP; Orlando KA; Yap D; Kommoss F; Bally MB; Morin GB; Trent JM; Weissman BE; Huntsman DG
J Pathol; 2017 Jul; 242(3):371-383. PubMed ID: 28444909
[TBL] [Abstract][Full Text] [Related]
27. Germline SMARCA4 mutations in patients with ovarian small cell carcinoma of hypercalcemic type.
Moes-Sosnowska J; Szafron L; Nowakowska D; Dansonka-Mieszkowska A; Budzilowska A; Konopka B; Plisiecka-Halasa J; Podgorska A; Rzepecka IK; Kupryjanczyk J
Orphanet J Rare Dis; 2015 Mar; 10():32. PubMed ID: 25886974
[TBL] [Abstract][Full Text] [Related]
28. Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade.
Jelinic P; Ricca J; Van Oudenhove E; Olvera N; Merghoub T; Levine DA; Zamarin D
J Natl Cancer Inst; 2018 Jul; 110(7):787-790. PubMed ID: 29365144
[TBL] [Abstract][Full Text] [Related]
29. Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): Comprehensive management of a newly diagnosed young adult.
Pressey JG; Dandoy CE; Pater LE; Sroga Rios J; Sisson R; Dasgupta R; Szabo S
Gynecol Oncol; 2020 Sep; 158(3):538-546. PubMed ID: 32654763
[TBL] [Abstract][Full Text] [Related]
30. Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.
Wang Y; Chen SY; Colborne S; Lambert G; Shin CY; Santos ND; Orlando KA; Lang JD; Hendricks WPD; Bally MB; Karnezis AN; Hass R; Underhill TM; Morin GB; Trent JM; Weissman BE; Huntsman DG
Mol Cancer Ther; 2018 Dec; 17(12):2767-2779. PubMed ID: 30232145
[TBL] [Abstract][Full Text] [Related]
31. No small surprise - small cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour.
Foulkes WD; Clarke BA; Hasselblatt M; Majewski J; Albrecht S; McCluggage WG
J Pathol; 2014 Jul; 233(3):209-14. PubMed ID: 24752781
[TBL] [Abstract][Full Text] [Related]
32. SMARCA4-deficient rhabdoid tumours show intermediate molecular features between SMARCB1-deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type.
Andrianteranagna M; Cyrta J; Masliah-Planchon J; Nemes K; Corsia A; Leruste A; Holdhof D; Kordes U; Orbach D; Corradini N; Entz-Werle N; Pierron G; Castex MP; Brouchet A; Weingertner N; Ranchère D; Fréneaux P; Delattre O; Bush J; Leary A; Frühwald MC; Schüller U; Servant N; Bourdeaut F
J Pathol; 2021 Sep; 255(1):1-15. PubMed ID: 33999421
[TBL] [Abstract][Full Text] [Related]
33. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
[TBL] [Abstract][Full Text] [Related]
34. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary.
Xue Y; Meehan B; Macdonald E; Venneti S; Wang XQD; Witkowski L; Jelinic P; Kong T; Martinez D; Morin G; Firlit M; Abedini A; Johnson RM; Cencic R; Patibandla J; Chen H; Papadakis AI; Auguste A; de Rink I; Kerkhoven RM; Bertos N; Gotlieb WH; Clarke BA; Leary A; Witcher M; Guiot MC; Pelletier J; Dostie J; Park M; Judkins AR; Hass R; Levine DA; Rak J; Vanderhyden B; Foulkes WD; Huang S
Nat Commun; 2019 Feb; 10(1):558. PubMed ID: 30718512
[TBL] [Abstract][Full Text] [Related]
35. Dedifferentiated and Undifferentiated Ovarian Carcinoma: An Aggressive and Molecularly Distinct Ovarian Tumor Characterized by Frequent SWI/SNF Complex Inactivation.
Tessier-Cloutier B; Kommoss FKF; Kolin DL; Němejcová K; Smith D; Pors J; Stewart CJR; McCluggage WG; Foulkes WD; von Deimling A; Köbel M; Lee CH
Mod Pathol; 2024 Jan; 37(1):100374. PubMed ID: 37925057
[TBL] [Abstract][Full Text] [Related]
36. Ovarian carcinoma in children with constitutional mutation of SMARCA4: single-family report and literature review.
Pastorczak A; Krajewska K; Urbanska Z; Szmyd B; Salacinska-Los E; Kobos J; Mlynarski W; Trelinska J
Fam Cancer; 2021 Oct; 20(4):355-362. PubMed ID: 33907931
[TBL] [Abstract][Full Text] [Related]
37. Small Cell Carcinoma of Ovary, Hypercalcemic Type (Malignant Rhabdoid Tumor of Ovary) with Loss of SMARCA4 (BRG1) Expression: Report of Two Cases.
Sahay A; Kante K; Menon S; Ghosh J; Kerkar RA; Deodhar KK
Turk Patoloji Derg; 2020; 1(1):261-267. PubMed ID: 32149361
[TBL] [Abstract][Full Text] [Related]
38. Ovarian small cell carcinoma in one of a pair of monozygous twins.
Fahiminiya S; Sabbaghian N; Albrecht S; Nadaf J; Callegaro-Filho D; Foulkes WD
Fam Cancer; 2019 Apr; 18(2):161-163. PubMed ID: 30284660
[TBL] [Abstract][Full Text] [Related]
39. A tumor-derived population (SCCOHT-1) as cellular model for a small cell ovarian carcinoma of the hypercalcemic type.
Otte A; Göhring G; Steinemann D; Schlegelberger B; Groos S; Länger F; Kreipe HH; Schambach A; Neumann T; Hillemanns P; Park-Simon TW; Hass R
Int J Oncol; 2012 Aug; 41(2):765-75. PubMed ID: 22581215
[TBL] [Abstract][Full Text] [Related]
40. Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
Ramos P; Karnezis AN; Hendricks WP; Wang Y; Tembe W; Zismann VL; Legendre C; Liang WS; Russell ML; Craig DW; Farley JH; Monk BJ; Anthony SP; Sekulic A; Cunliffe HE; Huntsman DG; Trent JM
Rare Dis; 2014; 2(1):e967148. PubMed ID: 26942101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
